Literature DB >> 6978407

Immunoregulation by alpha 1 antitrypsin.

S N Breit, J P Robinson, E Luckhurst, P Clark, R Penny.   

Abstract

alpha 1 antitrypsin (alpha 1 AT) deficiency is a common genetic disorder seen in about 10% of the population. It predisposes to the development of a large number of inflammatory and immunologic disorders including rheumatoid arthritis, systemic lupus erythematosus, juvenile chronic arthritis, anterior uveitis, ankylosing spondylitis, fibrosing alveolitis and emphysema. We have investigated immunologic function in subjects with severe alpha 1 AT deficiency and demonstrated serum mediated enhancement of lymphocyte response to PHA and increased zymosan activation of mononuclear cells and neutrophils as measured by their chemiluminescence. These patients also have accelerated delayed hypersensitivity responses and increased levels of factor B, C3 and C5 but normal levels of immunoglobulin and other complement components. Such abnormalities in immunoregulation demonstrate a tendency to hyperreactivity that may contribute to disease predisposition.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6978407

Source DB:  PubMed          Journal:  J Clin Lab Immunol        ISSN: 0141-2760


  4 in total

Review 1.  Lung disease associated with alpha1-antitrypsin deficiency.

Authors:  Rubin M Tuder; Sabina M Janciauskiene; Irina Petrache
Journal:  Proc Am Thorac Soc       Date:  2010-11

2.  Alpha-1 anti-trypsin and CD30 expression occur in parallel in activated T cells.

Authors:  M S Bashir; D B Jones; D H Wright
Journal:  Clin Exp Immunol       Date:  1992-06       Impact factor: 4.330

3.  Lymphocyte cytotoxicity to autologous hepatocytes in alpha 1-antitrypsin deficiency.

Authors:  M Mondelli; G Mieli-Vergani; A L Eddleston; R Williams; A P Mowat
Journal:  Gut       Date:  1984-10       Impact factor: 23.059

Review 4.  Hepatic and Extrahepatic Sources and Manifestations in Endoplasmic Reticulum Storage Diseases.

Authors:  Francesco Callea; Paola Francalanci; Isabella Giovannoni
Journal:  Int J Mol Sci       Date:  2021-05-28       Impact factor: 5.923

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.